News Breaks |
|
|
| September 11, 2012 |
| 10:21 EDT |  | BMY, CTRX, OFC, PACW, SYNC | On The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Bristol-Myers (BMY) upgraded to Conviction Buy from Buy at Goldman... Catamaran (CTRX) upgraded to Conviction Buy from Buy at Goldman... Corporate Office Properties (OFC) upgraded to Neutral from Underweight at JPMorgan... PacWest Bancorp (PACW) upgraded to Outperform from Neutral at Macquarie... Synacor (SYNC) upgraded to Neutral from Sell at Citigroup. |
|
|
News For BMY;CTRX;OFC;PACW;SYNC From The Last 14 Days Check below for free stories on BMY;CTRX;OFC;PACW;SYNC the last two weeks. |
|
|
| May 17, 2013 |
| 13:21 EDT |  | BMY | Options with increasing implied volatility: CPRT BMY GDI HNZ
 Subscribe for More Information |
|
| May 16, 2013 |
| 16:32 EDT |  | BMY | Bristol-Myers announces intention to voluntarily delist preferred stock
Subscribe for More Information |
|
| 15:14 EDT |  | OFC | Corporate Office Properties management to meet with JPMorgan
Subscribe for More Information |
|
| 13:20 EDT | | BMY | Follow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares. |
|
| 13:14 EDT | | BMY | Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information |
|
| 08:55 EDT | | BMY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| 08:38 EDT |  | BMY | Bristol-Myers shares likely to give back recent gains, says Leerink
Leerink expects shares of Bristol-Myers to give back recent gains after ASCO published abstracts last night. The firm found the abstracts as in-line with, but not above, its expectations for nivolumab alone or immuno-oncology combination therapy and keeps a Market Perform rating on Bristol-Myers. |
|
| 05:52 EDT | | BMY | Stocks with implied volatility movement; BMY SLV
Subscribe for More Information |
|
| May 15, 2013 |
| 11:28 EDT | | BMY | Options with increasing implied volatility: BMY AGNC EBIX IAU
Subscribe for More Information |
|
| 09:43 EDT | | BMY | Active equity option families trading on open
Subscribe for More Information |
| |
| May 14, 2013 |
| 09:54 EDT | | SYNC | Synacor to present Cloud ID with Google+
Synacor (SYNC) announced it will demo Cloud ID Social Login with Google+ and advanced TV Everywhere technologies in the Developer Sandbox at Google I/O, May 15-17. |
|
| 07:24 EDT | | BMY | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 10, 2013 |
| 11:48 EDT |  | BMY | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| May 9, 2013 |
| 10:17 EDT | | BMY | Shire trades higher in London amid takeover chatter, Guardian says
Subscribe for More Information |
|
| May 8, 2013 |
| 10:33 EDT | | BMY | Bristol-Myers, Pfizer announced results from ARISTOTLE trial subanalysis
Bristol-Myers (BMY) and Pfizer (PFE) announced yesterday that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from the subanalysis showed that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis compared to warfarin in the ARISTOTLE trial were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation. This story corrects a headline from yesterday. |
|
| 09:41 EDT | | SYNC | Synacor upgraded to Overweight from Market Perform at Albert Fried
Price target is $6. |
|
| 09:00 EDT |  | SYNC | Synacor falls 10.4%
Synacor is down 10.4%, or 37c, to $3.18 |
|
| May 7, 2013 |
| 16:18 EDT |  | SYNC | Synacor sees FY13 revenue $122.0M-$126.0M, consensus $123.10M
Subscribe for More Information |
|
| 16:18 EDT | | SYNC | Synacor sees Q2 revenue $26.5M-$27.5M, consensus $30.64
Subscribe for More Information |
|
| 16:16 EDT | | SYNC | Synacor reports Q1 EPS with items 0c, consensus 0c
Reports Q1 revenue $29.1M, consensus $29.06M. Q1 net income includes stock-based compensation expense of $600,000 or 2c per share. |
| |
|
|
|
|
